Harte Hanks, Inc. (NYSE:HHS) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm. The stock boasts a consensus analyst “Buy” rating with the consensus recommendation standing at 2.00. This is according to all covering research brokerage firms taken into consideration by First Call. The consensus price target of $2.50 also implies significant upside from the current price of $1.03.
At the time of writing, the stock was trading at $1.03. This represents a change from most recent open price of 0.63%. In terms of performance, year to date, the stock is -35.10%. The monthly stock performance comes in at -23.44%. For the quarter, shares are performing at -32.88%. Weekly performance analysis shows the equity at -15.52%.
In taking a look at technical levels, shares are trading -21.08% away from the 50 day simple moving average and -30.08% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -47.63% away from it’s 52- week high and 8.04% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Harte Hanks, Inc.’s RSI stands at 30.12. In looking at volatility levels, the shares saw weekly volatility of 9.71% and 6.40% over the past month.
Stock research firms currently have a positive stance on shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE). Analysts are projecting that the stock will reach $32.71 on a short term (1 year) basis.
The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 1.60. This is based on the research brokerage reports taken into consideration by Thomson Reuters.
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) shares typically trade an average volume of 397.38 and institutions hold 27.80% of the total shares.
We see here that the stock is 3.20% away from the 20-Day Simple Moving Average. Their 50-Day Simple Moving Average is a difference of -6.66% from current levels. Further back, their 200-Day Simple Moving Average is 10.41% difference from today’s price. Currently, the stock is -27.55% from its 50-Day High and 15.54% from the 50-day low.
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)‘s stock has performed at 15.20%. Breaking that down further, it has performed 8.13% for the week, -4.32% for the month, -8.46% over the last quarter, 21.35% for the past half-year and 137.88% for this last year.